Research Projects Page

This study highlighted baseline factors associated with HCV treatment failure in 1,253 patients at four United States institutions. Most likely predictors of treatment failure in our dataset were older age, presence of hepatocellular carcinoma, and private versus public insurance, which appeared in 89%, 84%, and 80% of bootstrap models, respectively.

In this case series, we discuss 7 males between 17 and 39 years of age who reported testicular pain or discomfort within the first two weeks of starting therapy. The precise mechanism of this side effect is unknown, but it may be related to restoration of CFTR function in the male reproductive tract. All patients experienced resolution of this side effect within a week after onset, regardless of the management, exception for one patient.

In this study, we examined patients with osteoporosis prescribed denosumab. We explored the association between treatment lapses and discontinuations with fracture incidence. We also assessed reasons patients incurred a lapse in therapy or discontinued treatment, and discussed the role of the specialty pharmacist in supporting patient adherence and persistence.

The purpose of this study was to explore student education about HIV and related topics using a cross-sectional, population-based survey of U.S. pharmacy schools with a 15-item questionnaire. We found diversity in the amount of time devoted to HIV didactic education among the 37 U.S. pharmacy schools who completed the survey, with some schools providing minimal didactic teaching on the topic of HIV along with low rates of exposure to PLWH in experiential training.

This study found that integrating a pharmacist into clinic significantly shortened time from treatment decision to shipment for LDD drugs, partially overcoming access barriers. Additionally, access to LDDs was still slower than non-LDDs as they cannot be fully integrated into clinic workflow. The integrated specialty pharmacy program adds value to patient access and outperforms LDDs, challenging the value of LDD networks beyond medical economics.

Immunomodulatory therapies for multiple myeloma can increase patient risk for venous thromboembolism (VTE). This phase IV single-arm study assessed the rate of symptomatic VTE over 6 months in 50 patients with multiple myeloma receiving immunomodulatory therapy and apixaban for primary prevention. No patients experienced symptomatic VTE or a major hemorrhage and 3 patients experienced clinically relevant non-major hemorrhage but were able to resume apixaban after medical management.

The purpose of this initiative was to develop a tool to assess quality in the use of TKIs to manage NSCLC and ultimately track variables such as proper medication use, patient safety and healthcare resource utilization.

The purpose of this study was to assess medication non-adherence [defined as medication possession ratio (MPR)]and validate the findings of risk factors for non-adherence to biologic therapy for adult inflammatory bowel disease: narcotic use, psychiatric diagnosis history, prior biologic use, and smoking. This study found that previously identified cumulative risk factors remain significant.

The objective of this study was to better define the association of hepatitis C-positive donors with heart transplant volumes, wait-list duration, and mortality at 1 year. Findings suggest that infection is well-tolerated and curable in heart transplant recipients with donor-derived hepatitis C, and 1-year survival is equivalent to that in recipients of hepatitis C-negative donors.